(R)-70

(R)-70
Clinical data
Other names	R-70
Drug class	Non-hallucinogenic Serotonin 5-HT2A receptor agonist
ATC code	None;
Identifiers
	IUPAC name 3-[(3R)-1,3-dimethyl-3,6-dihydro-2H-pyridin-5-yl]-1H-pyrrolo[2,3-b]pyridine;
PubChem CID	170328782;
Chemical and physical data
Formula	C14H17N3
Molar mass	227.311 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CN(CC(=C1)C2=CNC3=C2C=CC=N3)C;
	InChI InChI=1S/C14H17N3/c1-10-6-11(9-17(2)8-10)13-7-16-14-12(13)4-3-5-15-14/h3-7,10H,8-9H2,1-2H3,(H,15,16)/t10-/m1/s1; Key:BVUHRQDBEWGRFX-SNVBAGLBSA-N;

(R)-70, or R-70, is a non-hallucinogenic selective serotonin 5-HT₂ receptor moderate-efficacy partial agonist of the tetrahydropyridinylpyrrolopyridine family related to the psychedelic tryptamines. It shows preference for activation of the serotonin 5-HT_2A receptor of about 6.4-fold relative to the serotonin 5-HT_2B receptor and of about 30-fold relative to the serotonin 5-HT_2C receptor. The drug is a biased agonist of the serotonin 5-HT_2A receptor, activating G_q protein signaling more readily than β-arrestin2 signaling. It did not significantly produce the head-twitch response in mice, but did produce antidepressant-like effects. (R)-70, along with its close analogue (R)-69, was first described in the scientific literature by Bryan L. Roth and colleagues in 2022. It was identified via an ultra-large-scale docking campaign for the serotonin 5-HT_2A receptor.